查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496163

全球神經內分泌腫瘤 (NET) 市場（2024 年版）：按治療、給藥途徑、適應症、最終用戶和區域、市場考慮因素和預測進行分析（2020-2030 年）

Global Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of Administration, By Indication, By End User, By Region: Market Insights and Forecast (2020-2030)
出版日期: | 出版商: Azoth Analytics | 英文 300 Pages | 訂單完成後即時交付

價格

2020-2023年全球神經內分泌腫瘤（NET）市場規模年複合成長率為8.98%。2023年市場規模為35.7億美元，預計2030年將達69.4億美元。由於 NET 的發病率和盛行率增加、醫療保健成本上升、老年人口增加、醫療保健基礎設施改善以及宣傳活動和患者支持活動不斷增加，該市場呈現顯著成長。

近年來，全球 NET 的發生率和盛行率顯著增加。多種因素促成了這一趨勢，包括診斷技術的改進導致檢出率更高、醫療保健專業人員的意識提高以及人口老化。隨著越來越多的病例被診斷出來，對 NET 患者的診斷測試、治療方案和支持性護理服務的需求不斷增加。

此外，隨著標靶治療藥物和新治療方法的出現，NET的治療發生重大變化。生長抑制素類似物如Octreotide和Lanreotide可控制荷爾蒙症狀並抑制某些 NET 亞型的腫瘤生長。 PRRT 對表達生長抑制素受體的癌細胞進行標靶放射治療，為晚期疾病患者提供了一種有前途的治療選擇。此外，進行的免疫療法、聯合治療和基於基因的方法的研究有可能進一步擴大 NET 的治療方法，推動市場成長。

精準醫學和分子診斷的進步使得針對個別腫瘤分子特徵的個人化治療策略成為可能。生物標記主導的方法根據特定的腫瘤標記、生長抑制素受體表達模式和基因變化來識別最有可能從 SSA 治療中受益的患者。這允許更有針對性和更有效的治療選擇，最佳化治療結果，同時最大限度地減少不必要的藥物暴露。

奈米技術的進步也促進了用於 NET 治療胃腸外給藥的微球和奈米顆粒製劑的開發。這些製劑將藥物封裝在生物分解性的聚合物基質或脂質奈米顆粒中，可以控制釋放並靶向遞送至腫瘤組織。微球和奈米顆粒製劑具有提高藥物穩定性、增強腫瘤滲透性和延長體內循環時間等優點。透過最佳化藥物藥物動力學和生物分佈，這些製劑可改善治療結果，同時最大限度地減少脫靶效應。

進行的研究調查用於胃腸道 NET局部藥物傳輸和影像引導治療的靶向內視鏡輸送系統。藥物釋放型支架、顯微注射器和磁導航系統等新型內視鏡平台能夠將治療藥物直接精確地輸送到腫瘤部位。這些標靶遞送系統可以提高化療、免疫療法和胜肽受體放射性核素療法（PRRT）等治療方法的療效和安全性，同時最大限度地減少全身暴露和脫靶效應。即時成像和導航功能能夠精確定位和監測治療反應，最佳化治療結果，同時最大限度地減少手術併發症。

本報告調查全球神經內分泌腫瘤（NET）市場，並提供了包括市場規模和預測、區域和細分分析以及主要趨勢和機會在內的資訊。

目錄

第1章 市場背景

  • 產品範圍和產品前景
  • 執行摘要
  • 調查方法

第2章 戰略建議

  • 設立專門治療中心
  • 意識提升宣傳活動的管理

第3章 全球神經內分泌腫瘤（NET）市場：實績與預測

  • 宏觀經濟因素對全球神經內分泌腫瘤（NET）市場的影響分析
  • 管道場景
  • 流行病學：全球 NET 盛行率
  • 流行病學：全球 NET 盛行率
  • 全球神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
  • COVID-19 對神經內分泌腫瘤（NET）市場的影響
  • 全球神經內分泌腫瘤（NET）市場細分：依治療方法
    • 全球神經內分泌腫瘤（NET）市場：依治療方法、概述
    • 全球神經內分泌腫瘤（NET）市場吸引力指數：依治療方法、概述
    • 全球神經內分泌腫瘤（NET）市場規模：生長抑制素類似物（SSA）（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：標靶治療（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：其他（金額）（2020-2030）
  • 全球神經內分泌腫瘤（NET）市場細分：依給藥途徑
    • 全球神經內分泌腫瘤（NET）市場：依給藥途徑、概述
    • 全球神經內分泌腫瘤（NET）市場吸引力指數：依給藥途徑，概述
    • 全球神經內分泌腫瘤（NET）市場規模：口服（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：腸外（金額）（2020-2030）
  • 全球神經內分泌腫瘤（NET）市場細分：按適應症
    • 全球神經內分泌腫瘤（NET）市場：按適應症、概述
    • 全球神經內分泌腫瘤（NET）市場吸引力指數：按適應症、概述
    • 全球神經內分泌腫瘤（NET）市場規模：肺內分泌腫瘤（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：胰臟內分泌腫瘤（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：胃腸道內分泌腫瘤（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：其他（金額）（2020-2030）
  • 全球神經內分泌腫瘤（NET）市場細分：依最終用戶
    • 全球神經內分泌腫瘤（NET）市場：依最終用戶分類，概述
    • 全球神經內分泌腫瘤（NET）市場吸引力指數：依最終用戶分類，概述
    • 全球神經內分泌腫瘤（NET）市場規模：醫院（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：專科診所（金額）（2020-2030）
    • 全球神經內分泌腫瘤（NET）市場規模：放射線中心（金額）（2020-2030）

第4章 全球神經內分泌腫瘤（NET）市場，區域分析

  • 研究的區域範圍
  • 區域簡介

第5章 美洲神經內分泌腫瘤（NET）市場：實績與預測

  • 美洲神經內分泌腫瘤（NET）市場：概述
  • 美洲神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
  • 美洲神經內分泌腫瘤（NET）市場：主要因素
  • 美洲神經內分泌腫瘤（NET）市場：細分分析
  • 美洲神經內分泌腫瘤（NET）市場細分：依治療方法
  • 美洲神經內分泌腫瘤（NET）市場細分：依給藥途徑
  • 美洲神經內分泌腫瘤（NET）市場細分：按適應症
  • 美洲神經內分泌腫瘤（NET）市場細分：依最終用戶
  • 美洲神經內分泌腫瘤（NET）市場細分：依國家
    • 歐洲神經內分泌腫瘤（NET）市場：依國家/地區分類，概述
    • 美國神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 加拿大神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 其他美洲神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）

第6章 歐洲神經內分泌腫瘤（NET）市場：實績與預測

  • 歐洲神經內分泌腫瘤（NET）市場：概述
  • 歐洲神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
  • 歐洲神經內分泌腫瘤（NET）市場：主要因素
  • 歐洲神經內分泌腫瘤（NET）市場：細分分析
  • 歐洲神經內分泌腫瘤（NET）市場細分：依治療方法
  • 歐洲神經內分泌腫瘤（NET）市場細分：依給藥途徑
  • 歐洲神經內分泌腫瘤（NET）市場細分：按適應症
  • 歐洲神經內分泌腫瘤（NET）市場細分：依最終用戶
  • 歐洲神經內分泌腫瘤（NET）市場細分：依國家/地區
    • 歐洲神經內分泌腫瘤（NET）市場：依國家/地區分類，概述
    • 英國神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 德國神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 法國神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 西班牙神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 其他歐洲神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）

第7章 亞太神經內分泌腫瘤（NET）市場：實績與預測

  • 亞太地區神經內分泌腫瘤（NET）市場：概述
  • 亞太地區神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
  • 亞太地區神經內分泌腫瘤（NET）市場：主要因素
  • 亞太地區神經內分泌腫瘤（NET）市場：細分分析
  • 亞太地區神經內分泌腫瘤（NET）市場區隔：依治療方法
  • 亞太地區神經內分泌腫瘤（NET）市場細分：依給藥途徑
  • 亞太地區神經內分泌腫瘤（NET）市場區隔：按適應症
  • 亞太地區神經內分泌腫瘤（NET）市場細分：依最終用戶
  • 亞太地區神經內分泌腫瘤（NET）市場細分：依國家/地區
    • 亞太地區神經內分泌腫瘤（NET）市場：依國家/地區分類，概述
    • 中國神經內分泌腫瘤（NET）市場：市場規模及年複合成長率（2020-2030）
    • 日本神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 印度神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 韓國神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
    • 其他亞太地區神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）

第8章 中東和非洲神經內分泌腫瘤（NET）市場：實績與預測

  • 中東和非洲神經內分泌腫瘤（NET）市場：概述
  • 中東和非洲神經內分泌腫瘤（NET）市場：市場規模和年複合成長率（2020-2030）
  • 中東和非洲神經內分泌腫瘤（NET）市場：主要因素
  • 中東和非洲神經內分泌腫瘤（NET）市場：細分分析
  • 中東和非洲神經內分泌腫瘤（NET）市場細分：依治療方法
  • 中東和非洲神經內分泌腫瘤（NET）市場細分：依給藥途徑
  • 中東和非洲神經內分泌腫瘤（NET）市場細分：按適應症
  • 中東和非洲神經內分泌腫瘤（NET）市場細分：依最終用戶

第9章 市場動態

  • 評估市場動態對全球神經內分泌腫瘤（NET）市場的影響
  • 促進因素
  • 抑制因素
  • 趨勢

第10章 產業生態系分析

  • 波特分析

第11章 競爭定位

  • 企業產品定位
  • 主要企業市場佔有率
  • 公司簡介
    • Novartis
    • Pfizer
    • Amgen, Inc.
    • GlaxoSmithKline
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Co.
    • Eli Lilly and Company
    • Ipsen
    • Lantheus Holdings
    • Boehringer Ingelheim

第12章 關於公司、免責聲明

Executive Summary

Azoth Analytics has released a research report titled "Global Neuroendocrine Tumors (NETs) Market (2024 Edition)" which provides a complete analysis of the Global Neuroendocrine Tumors (NETs) industry in terms of market segmentation by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), by Route of Administration (Oral, Parenteral), by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others), by End User (Hospitals, Specialty Clinics, Radiation Centers) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea). The Global Neuroendocrine Tumors (NETs) market showcased growth at a CAGR of 8.98% during 2020-2023. The market was valued at USD 3.57 Billion in 2023 which is expected to reach USD 6.94 Billion in 2030. The market for Neuroendocrine Tumors (NETs) has seen significant growth due to the increasing incidence and prevalence of NETs, rising healthcare expenditure, a growing geriatric population, improvements in healthcare infrastructure, and heightened awareness campaigns and patient advocacy efforts.

Over recent years, there has been a notable rise in the incidence and prevalence of NETs globally. Several factors contribute to this trend, including improved diagnostic techniques leading to better detection rates, heightened awareness among healthcare professionals, and an aging population. As more cases are diagnosed, the demand for diagnostic tests, treatment options, and supportive care services for NET patients continues to grow.

Furthermore, the emergence of targeted therapies and novel treatment modalities has transformed the management of NETs. Somatostatin analogs, such as octreotide and lanreotide, control hormonal symptoms and inhibit tumor growth in certain subtypes of NETs. PRRT delivers targeted radiation to tumor cells expressing somatostatin receptors, offering a promising therapeutic option for patients with advanced disease. Furthermore, ongoing research into immunotherapies, combination therapies, and gene-based approaches holds potential for further expanding the treatment armamentarium for NETs, driving market growth.

Advancement in precision medicine and molecular diagnostics enable personalized treatment strategies tailored to the molecular characteristics of individual tumors. Biomarker-driven approaches identify patients who are most likely to benefit from SSA therapy based on specific tumor markers, somatostatin receptor expression patterns, and genetic alterations. This allows for more targeted and effective treatment selection, optimizing therapeutic outcomes while minimizing unnecessary exposure to medications.

Also, advancement in nanotechnology enable the development of microsphere and nanoparticle formulations for parenteral administration of NETs therapies. These formulations encapsulate the drug within biodegradable polymer matrices or lipid-based nanoparticles, allowing for controlled release and targeted delivery to tumor tissues. Microsphere and nanoparticle formulations offer advantages such as improved drug stability, enhanced tumor penetration, and prolonged circulation time in the body. By optimizing drug pharmacokinetics and biodistribution, these formulations enhance treatment outcomes while minimizing off-target effects.

Ongoing research explores targeted endoscopic delivery systems for localized drug delivery and image-guided therapy in gastrointestinal NETs. Novel endoscopic platforms, such as drug-eluting stents, micro-injectors, and magnetic navigation systems, enable precise delivery of therapeutic agents directly to the tumor site. These targeted delivery systems enhance the efficacy and safety of treatment modalities, such as chemotherapy, immunotherapy, and peptide receptor radionuclide therapy (PRRT), by minimizing systemic exposure and off-target effects. Real-time imaging and navigation capabilities allow for precise localization and monitoring of therapeutic response, optimizing treatment outcomes while minimizing procedural complications.

Scope of the Report:

  • The report analyses the Neuroendocrine Tumors (NETs) Market by Value (USD Million).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Pipeline Scenario.
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Epidemiology.
  • The report presents the analysis of Neuroendocrine Tumors (NETs) Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Route of Administration (Oral, Parenteral).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others).
  • The report analyses the Neuroendocrine Tumors (NETs) Market by End User (Hospitals, Specialty Clinics, Radiation Centers).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by source, by application, by indication, & by end user.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Pfizer, Amgen, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Ipsen, Lantheus Holdings, and Boehringer Ingelheim.

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

  • 2.1 Establishment of specialist therapeutic centers
  • 2.2 Organize campaigns to raise awareness

3. Global Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 3.1 Impact Analysis of Macro Economic Factors on Global Neuroendocrine Tumors (NETs) Market
  • 3.2 Pipeline Scenario
  • 3.3 Epidemiology: Global NETs Prevalence
  • 3.4 Epidemiology: Global NETs Incidence
  • 3.5 Global Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 3.6 Degree of Impact of Covid-19 on Neuroendocrine Tumors (NETs) Market
  • 3.7 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 3.7.1 Global Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 3.7.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Therapy Overview
    • 3.7.3 Global Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 3.7.4 Global Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.7.5 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 3.8.1 Global Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 3.8.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Route of Administration Overview
    • 3.8.3 Global Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.4 Global Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 3.9.1 Global Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 3.9.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Indication Overview
    • 3.9.3 Global Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.4 Global Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.5 Global Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.6 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.10 Global Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 3.10.1 Global Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 3.10.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By End User Overview
    • 3.10.3 Global Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.10.4 Global Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics By Value, 2020H-2030F (USD Million & CAGR)
    • 3.10.5 Global Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

4. Global Neuroendocrine Tumors (NETs) Market, Region Analysis

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 5.1 Americas Neuroendocrine Tumors (NETs) Market: Snapshot
  • 5.2 Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 5.3 Americas Neuroendocrine Tumors (NETs) Market: Key Factors
  • 5.4 Americas Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 5.5 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 5.5.1 Americas Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 5.5.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.6 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 5.6.1 Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 5.6.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.6.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 5.7.1 Americas Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 5.7.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.5 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.8 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 5.8.1 Americas Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 5.8.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.8.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.8.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.9 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Country
    • 5.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
    • 5.9.2 United States Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.2.1 United States Neuroendocrine Tumors (NETs) Market, By Therapy
      • 5.9.2.2 United States Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 5.9.2.3 United States Neuroendocrine Tumors (NETs) Market, By Indication
      • 5.9.2.4 United States Neuroendocrine Tumors (NETs) Market, By End User
    • 5.9.3 Canada Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.3.1 Canada Neuroendocrine Tumors (NETs) Market, By Therapy
      • 5.9.3.2 Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 5.9.3.3 Canada Neuroendocrine Tumors (NETs) Market, By Indication
      • 5.9.3.4 Canada Neuroendocrine Tumors (NETs) Market, By End User
    • 5.9.4 Rest of Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.4.1 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy
      • 5.9.4.2 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 5.9.4.3 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication
      • 5.9.4.4 Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User

6. Europe Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 6.1 Europe Neuroendocrine Tumors (NETs) Market: Snapshot
  • 6.2 Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 6.3 Europe Neuroendocrine Tumors (NETs) Market: Key Factors
  • 6.4 Europe Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 6.5 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 6.5.1 Europe Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 6.5.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.6 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 6.6.1 Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 6.6.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.6.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 6.7.1 Europe Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 6.7.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.5 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.8 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 6.8.1 Europe Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 6.8.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.8.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.8.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.9 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Country
    • 6.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
    • 6.9.2 United Kingdom Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.2.1 United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.2.2 United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.2.3 United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.2.4 United Kingdom Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.3 Germany Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.3.1 Germany Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.3.2 Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.3.3 Germany Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.3.4 Germany Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.4 France Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.4.1 France Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.4.2 France Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.4.3 France Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.4.4 France Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.5 Spain Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.5.1 Spain Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.5.2 Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.5.3 Spain Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.5.4 Spain Neuroendocrine Tumors (NETs) Market, By End User
    • 6.9.6 Rest of Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.6.1 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy
      • 6.9.6.2 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 6.9.6.3 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication
      • 6.9.6.4 Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User

7. Asia Pacific Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market: Snapshot
  • 7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market: Key Factors
  • 7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 7.5.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 7.5.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.6 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 7.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 7.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.6.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 7.7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 7.7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.8 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 7.8.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 7.8.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.8.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.8.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.9 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Country
    • 7.9.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Country Overview
    • 7.9.2 China Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.2.1 China Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.2.2 China Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.2.3 China Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.2.4 China Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.3 Japan Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.3.1 Japan Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.3.2 Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.3.3 Japan Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.3.4 Japan Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.4 India Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.4.1 India Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.4.2 India Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.4.3 India Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.4.4 India Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.5 South Korea Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.5.1 South Korea Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.5.2 South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.5.3 South Korea Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.5.4 South Korea Neuroendocrine Tumors (NETs) Market, By End User
    • 7.9.6 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.6.1 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy
      • 7.9.6.2 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration
      • 7.9.6.3 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication
      • 7.9.6.4 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User

8. Middle East and Africa Neuroendocrine Tumors (NETs) Market: Historic and Forecast

  • 8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Snapshot
  • 8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Key Factors
  • 8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Segment Analysis
  • 8.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
    • 8.5.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Therapy Overview
    • 8.5.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.6 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
    • 8.6.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
    • 8.6.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.6.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
    • 8.7.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Indication Overview
    • 8.7.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.8 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By End User
    • 8.8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By End User Overview
    • 8.8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact assessment of Market Dynamics on Global Neuroendocrine Tumors (NETs) Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Porter Analysis

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Share of Leading Companies
  • 11.3 Company Profiling
    • 11.3.1 Novartis
    • 11.3.2 Pfizer
    • 11.3.3 Amgen, Inc.
    • 11.3.4 GlaxoSmithKline
    • 11.3.5 F. Hoffmann-La Roche AG
    • 11.3.6 Bristol-Myers Squibb Co.
    • 11.3.7 Eli Lilly and Company
    • 11.3.8 Ipsen
    • 11.3.9 Lantheus Holdings
    • 11.3.10 Boehringer Ingelheim

12. About Us and Disclaimer

List of Figures

  • Figure 1: Global Neuroendocrine Tumors (NETs) Market Size, By Value, 2020-2023 (USD Million)
  • Figure 2: Global Neuroendocrine Tumors (NETs) Market Size, By Value, 2024-2030 (USD Million)
  • Figure 3: Global Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 4: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Therapy (2025-2030)
  • Figure 5: Global Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 6: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Somatostatin Analogs (SSAs), 2020H-2030F (USD Million)
  • Figure 7: Global Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 8: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Targeted Therapy, 2020H-2030F (USD Million)
  • Figure 9: Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 10: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Others, 2020H-2030F (USD Million)
  • Figure 11: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Route of Administration (2025-2030)
  • Figure 12: Global Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 13: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Oral, 2020H-2030F (USD Million)
  • Figure 14: Global Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 15: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Parenteral, 2020H-2030F (USD Million)
  • Figure 16: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Indication (2025-2030)
  • Figure 17: Global Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 18: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Lung Endocrine Tumor, 2020H-2030F (USD Million)
  • Figure 19: Global Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 20: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Pancreatic Endocrine Tumor, 2020H-2030F (USD Million)
  • Figure 21: Global Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 22: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Gastrointestinal Endocrine Tumor, 2020H-2030F (USD Million)
  • Figure 23: Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 24: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Others, 2020H-2030F (USD Million)
  • Figure 25: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By End User (2025-2030)
  • Figure 26: Global Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 27: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Hospitals, 2020H-2030F (USD Million)
  • Figure 28: Global Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 29: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Specialty Clinics, 2020H-2030F (USD Million)
  • Figure 30: Global Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 31: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Radiation Centers, 2020H-2030F (USD Million)
  • Figure 32: Americas Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 33: Americas Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 34: Americas Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 35: Americas Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 36: Americas Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 37: Americas Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 38: Americas Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 39: Americas Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 40: Americas Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 41: Americas Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 42: Americas Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 43: Americas Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 44: Americas Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 45: Americas Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 46: United States Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 47: United States Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 48: United States Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 49: United States Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 50: United States Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 51: United States Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 52: Canada Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 53: Canada Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 54: Canada Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 55: Canada Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 56: Canada Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 57: Canada Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 58: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 59: Rest of Americas Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 60: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 61: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 62: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 63: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 64: Europe Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 65: Europe Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 66: Europe Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 67: Europe Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 68: Europe Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 69: Europe Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 70: Europe Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 71: Europe Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 72: Europe Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 73: Europe Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 74: Europe Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 75: Europe Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 76: Europe Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 77: Europe Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 78: United Kingdom Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 79: United Kingdom Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 80: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 81: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 82: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 83: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 84: Germany Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 85: Germany Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 86: Germany Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 87: Germany Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 88: Germany Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 89: Germany Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 90: France Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 91: France Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 92: France Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 93: France Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 94: France Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 95: France Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 96: Spain Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 97: Spain Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 98: Spain Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 99: Spain Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 100: Spain Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 101: Spain Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 102: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 103: Rest of Europe Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 104: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 105: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 106: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 107: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 108: Asia-Pacific Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 109: Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 110: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 111: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 112: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 113: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 114: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 115: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 116: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 117: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 118: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 119: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 120: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 121: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 122: China Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 123: China Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 124: China Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 125: China Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 126: China Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 127: China Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 128: Japan Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 129: Japan Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 130: Japan Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 131: Japan Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 132: Japan Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 133: Japan Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 134: India Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 135: India Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 136: India Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 137: India Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 138: India Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 139: India Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 140: South Korea Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 141: South Korea Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 142: South Korea Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 143: South Korea Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 144: South Korea Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 145: South Korea Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 146: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 147: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 148: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
  • Figure 149: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 150: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
  • Figure 151: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
  • Figure 152: Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 153: Middle East and Africa Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
  • Figure 154: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 155: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 156: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 157: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 158: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 159: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 160: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 161: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 162: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 163: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 164: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 165: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 166: Global Impact of Drivers and Restraints
  • Figure 167: Market Share of Prominent Companies of Neuroendocrine Tumors (NETs), 2023 (%)
  • Figure 168: Novartis Revenues, 2021-2023 (USD Billion)
  • Figure 169: Novartis Revenue , By Business Segments, 2023 (%)
  • Figure 170: Novartis Revenue , By Geographical Segments, 2023 (%)
  • Figure 171: Pfizer Revenues, 2021-2023 (USD Billion)
  • Figure 172: Pfizer Revenues, By Business Segments, 2023 (%)
  • Figure 173: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
  • Figure 174: Amgen, Inc. Revenues, 2021-2023 (USD Million)
  • Figure 175: Amgen, Inc. Revenues, By Geographic Segments, 2023 (%)
  • Figure 176: Amgen, Inc. Revenue , By Products, 2023 (%)
  • Figure 177: GSK Revenue, 2021-2023 (USD Billion)
  • Figure 178: GSK Revenue , By Business Segments, 2023 (%)
  • Figure 179: GSK Revenue, By Geographical Segment, 2023 (%)
  • Figure 180: Roche Revenues, 2021-2023 (USD Billion)
  • Figure 181: Roche Revenue , By Business Segment, 2023 (%)
  • Figure 182: Bristol-Myers Squibb Revenues, 2021-2023 (USD Billion)
  • Figure 183: Bristol-Myers Squibb Revenues, By Geographic Segments, 2023 (%)
  • Figure 184: Eli Lilly and Company Revenues, 2021-2023 (USD Billion)
  • Figure 185: Eli Lilly and Company Revenues, By Geographic Segments, 2023 (%)
  • Figure 186: Eli Lilly and Company Revenue , By Business Segments, 2023 (%)
  • Figure 187: Ipsen Revenues, 2021-2023 (USD Million)
  • Figure 188: Ipsen Revenue, By Business Segments, 2023 (%)
  • Figure 189: Ipsen Revenue, By Geographical Segments, 2023 (%)
  • Figure 190: Lantheus Revenues, 2021-2023 (USD Million)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Neuroendocrine Tumor (NETs) Therapies in Pipeline

Table A3: United States Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A4: United States Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A5: United States Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A6: United States Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A7: United States Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A8: United States Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A9: United States Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A10: United States Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A11: Canada Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A12: Canada Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A13: Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A14: Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A15: Canada Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A16: Canada Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A17: Canada Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A18: Canada Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A19: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A20: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A21: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A22: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A23: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A24: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A25: Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A26: Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A27: United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A28: United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A29: United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A30: United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A31: United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A32: United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A33: United Kingdom Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A34: United Kingdom Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A35: Germany Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A36: Germany Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A37: Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A38: Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A39: Germany Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A40: Germany Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A41: Germany Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A42: Germany Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A43: France Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A44: France Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A45: France Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A46: France Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A47: France Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A48: France Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A49: France Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A50: France Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A51: Spain Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A52: Spain Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A53: Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A54: Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A55: Spain Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A56: Spain Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A57: Spain Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A58: Spain Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A59: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A60: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A61: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A62: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A63: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A64: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A65: Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A66: Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A67: China Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A68: China Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A69: China Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A70: China Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A71: China Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A72: China Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A73: China Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A74: China Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A75: Japan Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A76: Japan Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A77: Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A78: Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A79: Japan Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A80: Japan Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A81: Japan Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A82: Japan Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A83: India Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A84: India Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A85: India Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A86: India Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A87: India Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A88: India Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A89: India Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A90: India Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A91: South Korea Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A92: South Korea Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A93: South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A94: South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A95: South Korea Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A96: South Korea Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A97: South Korea Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A98: South Korea Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A99: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A100: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A101: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A102: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A103: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A104: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A105: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A106: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A107: Novartis Key Company Financials, 2021-2023

Table A108: Pfizer Key Financials, 2021-2023

Table A109: Amgen, Inc. Key Financials, 2021-2023

Table A110: GSK Key Company Financials, 2021-2023

Table A111: Roche Key Financials, 2021-2023

Table A112: Bristol-Myers Squibb Key Financials, 2021-2023

Table A113: Eli Lilly and Company Key Financials, 2021-2023

Table A114: Ipsen Key Company Financials, 2021-2023

Table A115: Lantheus Key Company Financials, 2021-2023